Quick orientationEvidence update: 6 October 2026
What is GHK-Cu?
GHK-Cu is a naturally occurring three-amino-acid peptide that binds copper. Think of it as a tiny restoration specialist who refuses to work unless he has brought his own copper toolbox.
Why people are interested
The potential benefits, unpacked.
Here are the goals and claims that bring readers to this guide. The evidence note shows which part is demonstrated, early research or still a question.
The headline interest
Laboratory, wound-healing and cosmetic research explores collagen, skin appearance and repair biology.
What the mechanism suggests
Copper-binding tripeptide involved in extracellular-matrix and wound-response signalling; topical cosmetic use is distinct from injection.
What still needs proving
The key question is whether the claimed benefit has been demonstrated in controlled human studies using the same compound, route and population.
What is it actually doing?
Copper-binding tripeptide involved in extracellular-matrix and wound-response signalling; topical cosmetic use is distinct from injection.
The important distinction is between changing a biomarker or pathway and producing a meaningful outcome that people can feel, measure or sustain.
Results at a glanceHuman evidence
What did the studies actually find?
Human study deep dive
The most informative human evidence we could identify is translated below, with the original source linked.
Study evidenceStudy deep dives
The important studies, translated into normal English.
Each synopsis keeps the trial design, actual results and limitations together. Graphs below are redrawn from the cited numerical results so you can see the size of the effect without having to decode a journal figure.
Topical GHK-Cu after CO2 laser resurfacing — 2006
Randomised topical study · 13 completers · 12 weeksObjective analysis found no significant advantage for erythema, wrinkles or overall skin quality, although patient-rated satisfaction with overall skin quality was higher with the copper-peptide regimen.
GHK-Cu has extensive mechanistic biology, but the human clinical evidence is much thinner than internet claims suggest.
What it doesn't prove: Very small study and a post-laser setting; not evidence for injectable use.
Read the original study / source ↗
Dosing referenceResearch, licensed & reported protocols
What doses and schedules are actually documented?
Human research or licensed product information is separated from clinic and community practice. These are source-attributed reference protocols, not personalised dosing recommendations.
Human research / licensed or product dosing
| Protocol / context | Amount & frequency | Duration | Titration | Evidence |
|---|---|---|---|---|
| Human topical literature | Topical GHK-Cu-containing products used over weeks to months; exact active exposure often poorly specified | 12 weeks in a CO2-laser study | No titration | Small human cosmetic studies |
| Protocol / context | Amount & frequency | Duration | Titration | Evidence |
| 2026 evidence review | Clinical evidence remains sparse and formulations/doses are not quantitatively commensurable | — | — | Systematic/translational review |
Community / clinic / specialist protocols
| Pattern | Amount & frequency | Cycle | Progression | Status |
|---|---|---|---|---|
| Injectable lower pattern | 1 mg SC once daily | 4–8 weeks commonly discussed | Usually fixed | Community; not clinically validated |
| Injectable common pattern | 2 mg SC once daily | 4–8 weeks | Sometimes 1→2 mg | Community |
| Higher pattern | 2–3 mg SC daily | Several weeks | Often capped rather than escalated | Community; weaker support |
| Topical convention | ~0.05–0.1% to several-percent cosmetic formulations, usually 1–2× daily | Continuous | No titration | Product/cosmetic practice; formulation-specific |
The evidence for topical GHK-Cu cannot be used to validate systemic injection. Modern reviews explicitly describe the human clinical literature as thin and fragmented.
Evidence checked: 7 October 2026
Routes and formulations matter. A topical study does not validate injection; an IV research dose does not establish a fixed SC dose; and evidence for one molecular form must not be silently transferred to another.
Community reportsCommunity reports
What are people actually doing?
Community experience exists, but is anecdotal
Forums discuss schedules, effects and side effects, but posts are uncontrolled self-reports and product identity may be uncertain. Use them to understand what people report—not to estimate efficacy or establish a dose.
View the discussion on Reddit ↗
Safety and uncertaintySafety, side effects & what we don't know
Route matters: topical evidence cannot simply be transferred to injected products.
Product identity, sterility and concentration are additional uncertainties for unlicensed research products. Evidence from an approved medicine or a clinical trial should not be transferred automatically to a differently sourced product.
QuestionsQuestions worth asking
What is the strongest evidence here?
GHK-Cu has extensive mechanistic biology, but the human clinical evidence is much thinner than internet claims suggest.
Does a biological mechanism prove the claimed benefit?
No. Receptor activity, cell effects and animal results can justify research, but controlled human outcomes are a separate evidential step.
Is the research protocol a recommended dose?
No. The site reports study protocols to explain the evidence. It does not turn them into personalised self-use instructions.
Primary sourcesStudies, sources & further reading
External links are provided for transparency and further reading. Linking to a study, discussion or organisation does not mean Peptides Peptalk endorses every conclusion on that page.